 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease (11/19/2009)
Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.
Continuous Daily Sutent® Palliative in Patients with Relapsed or Refractory Advanced NSCLC (11/5/2009)
Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent® (sunitinib) was associated with a 25% disease control rate in patients with previously treated advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Amrubicin® and Paraplatin® Active and Tolerable in Elderly Patients with SCLC (10/22/2009)
Researchers from Japan have reported Amrubicin®, a new synthetic anthracycline, combined with Paraplatin® (carboplatin) resulted in an 89% overall response rate (ORR) in elderly patients with small cell lung cancer (SCLC). The details of this report appeared in an early online publication in the Annals of Oncology on October 13, 2009.
Maintenance Tarceva® Improves Overall Survival of Patients with Advanced NSCLC (9/28/2009)
Researchers affiliated with the SATURN study have reported that maintenance therapy with Tarceva® (erlotinib) improves overall survival (OS) in patients with advanced non–small cell lung cancer (NSCLC) who have no evidence of disease progression after four cycles of platinum-based induction therapy. The details of this randomized trial were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Iressa® Improves Progression-free Survival over Standard Chemotherapy in Patients with NSCLC with EGFR Mutations (9/28/2009)
Researchers from Japan have reported that Iressa® (gefitinib) alone improves outcomes of patients with non–small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) mutations compared with patients receiving Paraplatin® (carboplatin) and Taxol® (paclitaxel). The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Meta-analysis Confirms Effectiveness of Erbitux® in Advanced NSCLC (9/25/2009)
Researchers from several European medical centers have reported the results of a meta-analysis that demonstrates improvement in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) when Erbitux® (cetuximab) is added to platinum-based chemotherapy for patients with advanced non–small cell lung cancer (NSCLC). The details of this study were reported at the Joint ECCO 15-34th ESMO Multidisciplinary Congress in Berlin, September 20-24.
High Time Costs for Informal Care Givers of Cancer Patients (9/10/2009)
Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.
Large-scale Screening for EGFR Mutations Can Improve Outcomes in Lung Cancer (9/4/2009)
Researchers from Spain have reported that large-scale screening for epidermal growth factor receptor mutations in lung cancer is feasible and allows for customization of treatment with Tarceva® (erlotinib), thereby improving outcomes, according to the results of a study published early online in the New England Journal of Medicine on August 18, 2009.
Iressa® Superior to Paraplatin®/Taxol® in Advanced NSCLC (9/1/2009)
Researchers from Asia have reported that first-line treatment with Iressa® (gefitinib) improves progression-free survival over combination treatment with Paraplatin® (carboplatin) and Taxol® (paclitaxel) in advanced non–small cell lung cancer (NSCLC) among nonsmokers and former light smokers in East Asia, according to the results of a study published in the New England Journal of Medicine.
PET-CT Detects More Advanced Disease in Patients with NSCLC (8/20/2009)
Researchers from Canada have reported that preoperative whole-body positron emission tomography, computed tomography (PET-CT), and cranial imaging identifies more patients with mediastinal and extrathoracic non–small cell lung cancer (NSCLC) than conventional staging. However, some patients were upstaged incorrectly by PET-CT. The details of this study were reported in the August 16, 2009 issue of the Annals of Internal Medicine.
Paraplatin®, Taxol®, Erbitux®, and Avastin® Effective for Advanced NSCLC (8/12/2009)
Researchers affiliated with the Southwest Oncology Group (SWOG) have reported induction therapy with Paraplatin® (carboplatin), Taxol® (paclitaxel), Erbitux® (cetuximab), and Avastin® (bevacizumab) followed by maintenance Erbitux and Avastin is the most active regimen for advanced non–small cell lung (NSCLC) cancer studied by this group. The details of this study were presented at the 2009 meeting of the American Society of Clinical Oncology in May/June.
Neoadjuvant Chemotherapy and Radiotherapy Followed by Surgery May Improve Survival of Patients with Stage IIIB NSCLC (8/6/2009)
Researchers from Switzerland have reported that selected patients with Stage IIIB non–small cell lung cancer (NSCLC) may benefit from neoadjuvant chemotherapy and radiotherapy followed by surgery. The details of this study appeared in the August 1, 2009 issue of Lancet Oncology.
ASCO 2009: Phase I-II Results of New Bcl-2 Inhibitor, AT-101 (8/5/2009)
At the 2009 meeting of the American Society of Clinical Oncology (ASCO) there were several preclinical and Phase I-II clinical presentations suggesting activity for a new inhibitor of the Bcl-2 family of proteins (Bcl-2, Bcl-xL, Mel-1, Bcl-W), AT-109, developed by Ascenta Therapeutics.
Combination of Vidaza® and Entinostat Has Significant Activity in Relapsed NSCLC (8/4/2009)
Researchers from the Johns Hopkins Medical Institute and the Lovelace Respiratory Research Institute have reported that the combination of Vidaza® (5-azacitidine) and entinostat (SNDX-275) has significant activity in patients with advanced relapsed non–small cell lung cancer (NSCLC). The details of this study were presented at the 2009 meeting of the American Society of Clinical Oncology.
Maintenance Tarceva® Prolongs Progression-free Survival in Patients with Advanced NSCLC (7/31/2009)
Researchers affiliated with the SATURN study have reported that maintenance therapy with Tarceva® (erlotinib) improves progression-free survival in patients with non–small cell lung cancer (NSCLC) who have no evidence of disease progression after four cycles of platinum-based induction therapy. The details of this randomized trial were presented at the 2009 meeting of the American Society of Clinical Oncology in May/June.
Maintenance Alimta® Improves Survival in Non–Small Cell Lung Cancer (7/31/2009)
Researchers involved in an international randomized clinical trial have reported that continued treatment with Alimta® (pemetrexed) following initial chemotherapy significantly delays disease progression and improves median survival from 10.6 months to 13.4 months in patients with advanced non–small cell lung cancer (NSCLC). This effect was limited to patients with adenocarcinoma. These results were recently presented at the 2009 annual meeting of the American Society of Clinical Oncology in May/June.
Alimta®, Paraplatin®, and Avastin® with Alimta and Avastin Maintenance Effective for Nonsquamous NSCLC (7/30/2009)
Researchers from Northwestern University have reported that Alimta® (pemetrexed), Paraplatin® (carboplatin), and Avastin® (bevacizumab) with Alimta and Avastin maintenance is an effective regimen for treating patients with nonsquamous non–small cell lung cancer (NSCLC). The details of this study appeared in the July 10, 2009 issue of the Journal of Clinical Oncology.
Bilateral Oophorectomy Increases Risk of Lung Cancer (7/30/2009)
Researchers from Canada have reported that women who have bilateral oophorectomy are 1.92 times as likely to develop lung cancer as women who have natural menopause. The details of this study appeared in an early on-line publication in the International Journal of Cancer on May 11, 2009.
Thalidomide Doesn’t Benefit Patients with Small Cell Lung Cancer Treated with Etoposide and Carboplatin (7/24/2009)
Researchers from the U.K. have reported that treatment with a combination of thalidomide (Thalomid®) and chemotherapy did not improve survival among patients with small cell lung cancer, and resulted in a higher risk of blood clots than treatment with chemotherapy alone. The results of this study were published in the August issue of the Journal of the National Cancer Institute.
Schizophrenia Associated with Increased Cancer Mortality (7/22/2009)
Researchers from France have reported that persons with schizophrenia have an increased risk of mortality from cancer, especially from breast cancer for women and lung cancer for men. The details of this study appeared in the August, 2009 issue of Cancer.
False-positive Results Are Common with Cancer Screening (7/21/2009)
Researchers affiliated with the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial have reported that the risk of obtaining a false-positive result from screening for prostate, lung, colorectal, and ovarian cancer is high and becomes cumulatively higher with ongoing screening—after 14 screening tests, the cumulative risk of a false-positive is 60.4% for men and 48.8% for women. The results of this study were published in the May/June 2009 issue of the Annals of Family Medicine.
Steriotactic Radiotherapy Effective for Stage I NSCLC in Medically Inoperable Patients (7/13/2009)
Scandinavian researchers have reported that steriotactic radiotherapy for Stage I non–small cell lung cancer (NSCLC) is associated with a local control rate of 90% in patients deemed medically inoperable. These results were published in the July 10, 2009 issue of the Journal of Clinical Oncology.
Alimta® and Platinol® Confirmed Less Toxic than Gemzar® and Platinol for Advanced NSCLC (7/6/2009)
Researchers from Norway have reported that the combination of Alimta® (pemetrexed) and Platinol® (carboplatin) is as effective as the combination of Gemzar® (gemcitabine) and Platinol but is associated with less hematopoetic toxicity and less need for supportive care. The details of this randomized trial were published in the July 1, 2009 issue of the Journal of Clinical Oncology.
Preoperative PET-CT Reduces Number of Thoracotomies but Does Not Improve Survival of Patients with NSCLC (7/2/2009)
Researchers from Denmark have reported that “The use of PET-CT for preoperative staging of NSCLC [non–small cell lung cancer] reduced both the total number of thoracotomies and the number of futile thoracotomies but did not affect overall mortality.” The details of this study appeared in the July 2, 2009 issue of the New England Journal of Medicine.
Lung Cancer Screening with Low-dose Computed Tomography Associated with High Rate of False Positives (6/12/2009)
Researchers from the National Institutes of Health have reported that individuals who undergo lung cancer screening with low-dose computed tomography (LDCT) are at a high risk for receiving false-positive results. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on May 30.
Zactima™ Shows Promise Against Non–Small Cell Lung Cancer (6/8/2009)
Researchers affiliated with the ZODIAC international Phase III clinical trial have reported that the addition of Zactima™ (vandetanib) to Taxotere® (docetaxel) delayed time to progression among patients with previously treated, advanced non–small cell lung cancer (NSCLC). The details of this study were presented on May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Combined Hormone Replacement Therapy Linked to Increased Death Rate from NSCLC (6/5/2009)
Researchers affiliated with the Women’s Health Initiative (WHI) have reported that menopausal women with non–small cell lung cancer (NSCLC) who receive combined hormone replacement therapy (HRT) with estrogen plus progestin are 61% more likely to die from the disease than their counterparts who received placebo. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida on May 30.
Study Assesses Risk of Gastrointestinal Perforation in Patients Treated with Avastin® (6/1/2009)
Researchers from Stony Brook University Medical Center have reported that gastrointestinal perforation is a potentially serious side effect of Avastin® (bevacizumab). The details of this study appeared in the June, 2009 issue of Lancet Oncology.
Zactima™ Active in Advanced Non–Small Cell Lung Cancer (5/21/2009)
Researchers involved in an International randomized Phase II clinical trial have shown that Zactima™ (vandetanib) may be more effective than Iressa® (gefitinib) for second-line therapy of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC). The details of this study appeared in the May 20, 2009 issue of the Journal of Clinical Oncology.
Erbitux® Improves Survival in Patients with Advanced NSCLC (5/15/2009)
Researchers involved in a multicenter international trial have reported that the addition of Erbitux® (cetuximab) to platinum-based chemotherapy improves median survival by one month in patients with advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the May 2, 2009 issue of the Lancet.
First-line Iressa® Benefits EGFR-positive Patients with Advanced NSCLC Who Have Poor Performance Status (5/7/2009)
Researchers from Japan have reported that first-line Iressa® (gefitinib) provides benefit to patients with advanced non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations and an extremely poor performance status. The details of this study appeared in the March 20, 2009 issue of the Journal of Clinical Oncology.
Oophorectomy for Benign Disease Increases Heart- and Cancer-related Deaths (4/30/2009)
Researchers affiliated with the Harvard Nurses’ Health study have reported that women who have a hysterectomy and bilateral oophorectomy for benign disease have a lower risk of developing ovarian cancer but a higher risk of all-cause mortality, including cancer deaths, than women who have a hysterectomy without ooophorectomy. The details of this study appeared in the May 1, 2009 issue of Obstetrics and Gynecology.
Smoking Kills More Than 440,000 People Each Year in the United States (4/27/2009)
According to an analysis by the U.S. Centers for Disease Control and Prevention (CDC), cigarette smoking and exposure to tobacco smoke cause at least 443,000 premature deaths each year in the United States alone. These results, based on data from 2000-2004, were published in the Morbidity and Mortality Weekly Report.
Beta-carotene, Retinol, and Lutein Supplements May Increase Risk of Lung Cancer (4/7/2009)
Researchers affiliated with the VITamins And Lifestyle (VITAL) cohort Study have reported that use of individual beta-carotene, retinol, or lutein supplements is linked with an increased risk of lung cancer. The details of this study appeared in the April 1, 2009 issue of the American Journal of Epidemiology.
Nonsteroidal Anti-inflammatory Drugs May Decrease Risk of Lung Cancer (4/3/2009)
Researchers from the Fred Hutchinson Cancer Research Center have reported that use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with a small reduced risk of lung cancer. The details of this study appeared in an early online publication in Cancer Epidemiology, Biomarkers and Prevention on March 17, 2009.
The Addition of Avastin® to Gemzar® and Platinol® Improves Outcomes of NSCLC (3/10/2009)
Researchers affiliated with the AVAIL trial have reported that the addition of Avastin® (bevacizumab) to Gemzar® (gemcitabine) and Platinol® (cisplatin) improves progression-free survival (PFS) and response rate in non–small cell lung cancer (NSCLC). The details of this randomized trial were reported in the March 10, 2009 issue of the Journal of Clinical Oncology.
Adjuvant Paclitaxel plus Carboplatin Does Not Improve Survival in Stage IB NSCLC (1/27/2009)
Researchers affiliated with CALGB study 9633 have reported that adjuvant chemotherapy does not provide a statistically significant survival advantage for patients with Stage IB non–small cell lung cancer (NSCLC). The details of this study were published in the November 1, 2008 issue of the Journal of Clinical Oncology.
Non-platinum Regimen Effective Palliation for Advanced NSCLC (12/5/2008)
Researchers from Japan have reported that a regimen of Navelbine® (vinorelbine) plus Gemzar® (gemcitabine) followed by Taxotere® (docetaxel) is as effective as Paraplatin® (carboplatin) and Taxol® (paclitaxel) for initial treatment of patients with advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the December 2008 issue of Lancet Oncology.
Gemzar® and Paraplatin® Equivalent to Platinol® and VePesid® for SCLC (12/4/2008)
Researchers from the United Kingdom have reported that a regimen of Gemzar® (gemcitabine) and Paraplatin® (carboplatin) is as effective palliation as standard Platinol® (cisplatin) and VePesid® (etoposide) for patients with poor-risk small cell lung cancer (SCLC) but with less toxicity. The details of this study appeared in an early online publication in Thorax on September 11, 2008.
Iressa® Improves Survival of EGFR-positive Lung Adenocarcinoma (12/3/2008)
Researchers from Japan have reported that Iressa® (gefitinib) improves survival in patients who have epidermal growth factor receptor (EGFR)-positive lung adenocarcinoma. The details of this study were reported in the December 1, 2008 issue of the Journal of Clinical Oncology.
Iressa® Equivalent to Taxotere® for Previously Treated NSCLC (12/2/2008)
Researchers affiliated with the international randomized trial, INTEREST, have reported that Iressa® (gefitinib) is non-inferior to Taxotere® (docetaxel) for salvage palliative treatment of patients with previously treated non–small cell lung cancer (NSCLC). The details of this study appeared in the November 22, 2008 issue of Lancet.
Pulmonary Scarring on Chest X-Ray Is Associated with Lung Cancer Incidence (12/1/2008)
Researchers affiliated with the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial have reported that pulmonary scarring is associated with the development of ipsilateral lung cancer. The details of this study were reported in the November 24, 2008 issue of the Archives of Internal Medicine.
Erbitux® and Paraplatin® plus a Taxane are Tolerable and Active for NSCLC (11/21/2008)
There have been two recent publications indicating that adding Erbitux® (cetuximab) to a taxane—Taxol® (paclitaxel) or Taxotere® (docetaxel)—is feasible and effective initial therapy for patients with advanced non–small cell lung cancer (NSCLC).
Addition of Avastin® to Paraplatin®, Taxol®, and Erbitux® Promising for Advanced NSCLC (11/20/2008)
Researchers affiliated with the Southwest Oncology Group have reported that the four-drug combination of chemotherapy agents Paraplatin® (carboplatin) and Taxol® (paclitaxel) plus targeted therapies Avastin® (bevacizumab) and Erbitux® (cetuximab) is safe and may improve survival in patients with advanced non–small cell lung cancer (NSCLC). The details of this study were presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology November 13-15.
Avastin® Increases Risk of Venous Thromboembolism (11/20/2008)
Researchers from Stony Brook University have reported that the use of Avastin® (bevacizumab) increases the risk of thromboembolism. The details of this review were published in the November 19, 2008 issue of the Journal of the American Medical Association.
Non-Platinum Chemotherapy as Effective for SCLC (10/17/2008)
Researchers affiliated with the Cochrane Library have reported that chemotherapy regimens that do not contain platinum agents (Platinol and Paraplatin) appear to be just as effective as regimens that do contain platinum agents in the treatment of small cell lung cancer. These results were recently published in the Cochrane Database of Systematic Reviews.
Iressa® Confirmed Effective for Elderly with Non-Small Cell Lung Cancer (10/17/2008)
Researchers from Japan have reported that Iressa® (gefitinib) is effective and well tolerated for initial treatment of elderly patients with non-small cell lung cancer (NSCLC). The details of this study were published in the October, 2008 issue of the Journal of Thoracic Oncology.
Stereotactic Radiation Improves Local Control but Not Survival in Stage I NSCLC (10/1/2008)
Researchers from Denmark have reported that the addition of stereotactic radiation therapy in early-stage inoperable non–small cell lung cancer (NSCLC) improves local disease control but does not improve overall survival. These results were recently presented at the 2008 annual American Society of Therapeutic Radiology and Oncology (ASTRO).
Platinol®-Alimta® Less Toxic than Platinol®-Gemzar® for Advanced NSCLC (7/23/2008)
Researchers from Italy have reported that the combination of Platinol® (cisplatin) and Alimta® (pemetrexed) is less toxic and equally or more effective for initial therapy of patients with non–small cell carcinoma (NSCLC) than Platinol-Gemzar® (gemcitabine). The details of this study were published in the July 20, 2008 issue of the Journal of Clinical Oncology.
Radiofrequency Ablation Effective for Lung Tumors (7/22/2008)
Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.
Mutations of EGFR in Circulating Cancer Cells May Help Monitoring of Patients with NSCLC (7/9/2008)
Researchers from the Massachusetts General Hospital Cancer Center have reported that molecular analysis of circulating tumor cells in patients with non–small cell lung cancer (NSCLC) may provide a way to monitor treatment effectiveness. These results were published in an early online publication in the New England Journal of Medicine on July 2, 2008.
Preoperative Chemoradiotherapy Does Not Improve Survival of Stage III NSCLC (7/3/2008)
Researchers from Germany have reported that preoperative chemoradiotherapy does not improve survival of patients with Stage III non–small cell lung cancer (NSCLC) compared with preoperative chemotherapy alone. The details of this randomized trial were published in the July, 2008 issue of Lancet Oncology.
Beta-carotene in Multivitamins Harmful for Smokers (6/27/2008)
Researchers from the H. Lee Moffitt Cancer Center have reported that high-dose beta-carotene increases the risk of lung cancer in current smokers but not in former smokers. The details of this study were published in the July 1 issue of Cancer.
Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates (6/25/2008)
Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.
Nexavar® Delays Progression of Heavily Pre-treated NSCLC (6/6/2008)
Nexavar® (sorafenib) appears to significantly delay disease progression and provide a trend toward improved overall survival among patients with heavily pre-treated non–small cell lung cancer (NSCLC). These results were from a Phase II intergroup study with a randomized discontinuation design. Results were reported at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
VePesid®/Platinol® Remains Standard of Care for Small Cell Lung Cancer (6/6/2008)
Researchers affiliated with the Southwest Oncology Group (SWOG) reported that Camptosar® (irinotecan) plus Platinol® (cisplatin) did not demonstrate a survival improvement compared with VePesid® (etoposide)/cisplatin in the treatment of extensive-stage small cell lung cancer (SCLC). The SWOG researchers state that in North America, “etoposide remains the reference standard for treatment of SCLC.” These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Blood Test Shows Promise for Early Detection of Lung Cancer (6/6/2008)
According to the results of a study presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), an experimental blood test may eventually allow for earlier detection of lung cancer in smokers. The test assesses the presence of a lung cancer-associated RNA fingerprint in peripheral blood.
Maintenance Alimta® Delays Progression of Non–Small Cell Lung Cancer (5/30/2008)
Researchers from Romania have reported that continued treatment with Alimta® (pemetrexed) following initial chemotherapy significantly delays disease progression in patients with advanced or metastatic non–small cell lung cancer (NSCLC). These results were recently reported by the American Society of Clinical Oncology (ASCO) and will be presented at their upcoming 2008 annual meeting in Chicago May 30-June 3.
Aranesp® Does Not Increase the Relapse Rate in Patients with Advanced SCLC (5/19/2008)
Researchers involved in Amgen’s Aranesp pharmacovigilance program (the 145 Study) have reported that Aranesp® (darbepoetin alfa) has no adverse effect on outcomes of patients with extensive-stage small cell lung cancer (SCLC) receiving platinum-based chemotherapy. The details of this randomized Phase III study were published in the May 10, 2008 issue of the Journal of Clinical Oncology.
Surgery Effective in Very Elderly Patients with Lung Cancer (5/2/2008)
Researchers from the Hoag Cancer Center in California have reported that surgery for the treatment of non–small cell lung cancer (NSCLC) in patients 80 years and older is a safe and effective treatment approach for those who are eligible. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research.
Threefold Dose Intensity of ICE Does Not Improve Outcomes in Small Cell Lung Cancer (4/17/2008)
Researchers associated with the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation have reported that increasing the dose intensity of ICE (ifosfamide, carboplatin, and etoposide) by threefold by using peripheral blood stem cell support did not improve outcomes of patients with limited or extensive stage small cell lung cancer (SCLC). The details of this study appeared in an early online publication in the Journal of the National Cancer Institute on April 8, 2008.
PET Useful for Staging of Small Cell Lung Cancer (4/16/2008)
Researchers from West Virginia University have reported that positron emission tomography (PET) is useful for staging of small cell lung cancer (SCLC). The details of this study appeared in the January 2008 issue of Clinical Lung Cancer.
DNA Test Predicts Relapse of Stage I Lung Cancer (3/13/2008)
Researchers from Johns Hopkins University have reported that a gene profile was predictive of relapse in patients with surgically resected Stage I non–small cell lung cancer (NSCLC). The details of this study appeared in the March 13, 2008 issue of the New England Journal of Medicine.
Hormone Replacement Therapy Increases Cancer Risk (3/11/2008)
Researchers affiliated with the Women’s Health Initiative (WHI) have reported that hormone replacement therapy (HRT) increases the risk of breast cancer and lung cancer among postmenopausal women. These results were recently published in the March 5, 2008 issue of the Journal of the American Medical Association.
Sutent® Has Activity in Patients with Advanced Non–Small Cell Lung Cancer (3/6/2008)
Researchers involved in an international multicenter trial have reported that Sutent® (sunitinib) has significant single-agent activity in previously-treated, advanced non–small cell lung cancer (NSCLC). The details of this Phase II study were published in the February 1, 2008 issue of the Journal of Clinical Oncology.
High PET Uptake Value May Predict Relapses in Stage I NSCLC (3/3/2008)
Researchers from Washington University have reported that the maximum tumor standardized uptake value (SUVmax) of preoperative positron emission tomography (PET) is a predictor of relapse in patients with Stage I non–small cell lung cancer (NSCLC). The details of this study appeared in the February, 2008 issue of the Journal of Thoracic Oncology.
American Society of Clinical Oncology Provides Guidelines for Adjuvant Therapy of Non–Small Cell Lung Cancer (12/11/2007)
The American Society of Clinical Oncology and Cancer Care Ontario have published guidelines regarding the use of adjuvant chemotherapy and adjuvant radiation therapy in patients with Stage I-IIIA non–small cell lung cancer (NSCLC) that has been completely surgically removed. The guidelines were published in the December 1, 2007 issue of the Journal of Clinical Oncology.
Avastin® Associated Bowel Perforation Defined (12/4/2007)
Researchers from the MD Anderson Cancer Center have reported that the incidence of bowel perforation among patients receiving Avastin (bevacizumab) for a variety of malignancies was 1.7%. The details of this study appeared in an early on-line publication in the Annals of Oncology on November 16, 2007.
PET Scans May Help Identify Early Lung Cancer (12/3/2007)
A systematic review by Canadian researchers has concluded that positron emission tomography (PET) scans may improve the accuracy of imaging in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The details of this review appeared in an early on-line publication in the Journal of the National Cancer Institute on November 27, 2007.
Researchers Disagree with Conclusions of the International Lung Cancer Action Program on CT Screening (11/29/2007)
Researchers from several U.S. medical centers, the National Institutes of Health and the Nordic Cochrane Center have written a critique of the 2006 publication by the International Lung Cancer Action Program (I-ELCAP) that suggested CT screening for lung cancer was of proven benefit in improving survival. The details of this critique appeared in the November 26, 2007 issue of the Archives of Internal Medicine.
CT Still Not Recommended for Lung Cancer Screening (11/28/2007)
According to guidelines published by the American College of Chest Physicians, there is still no definitive evidence that screening methods such as low-dose computed tomography (CT) reduce the risk of death from lung cancer.
Baseline CT Screening Reported Useful for Asbestos Exposed Population (11/21/2007)
Researchers from Italy have reported that CT screening of persons exposed to asbestos is useful for the detection of early lung cancer. The details of this study appeared in the November, 2007 issue of The Oncologist.
Further Data Show Significantly Improved Survival with CT Screening for Lung Cancer (11/16/2007)
Researchers from Japan have reported that individuals undergoing low-dose computed tomography (CT) scans for early detection of lung cancer have a favorable mortality rate of less than 14% at 10 years following diagnosis. The details of this study were published in the December, 2007 issue of Lung Cancer.
Benefit of Prophylactic Cranial Irradiation in stage IIIA NSCLC Defined (11/13/2007)
Researchers from Germany have reported that patients with operable stage IIIA non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoradiotherapy benefit from prophylactic cranial irradiation (PCI). The details of this randomized study were published in the November 1, 2007 issue of the Journal of Clinical Oncology.
Screening CT Detects More Lung Cancers than Chest X-Ray at Baseline (11/7/2007)
Researchers from Italy have reported that CT detects four times more lung cancers than chest X-Ray.
Camptosar®-Platinum Regimens Confirmed Effective for Small Cell Lung Cancer (11/5/2007)
At the 12th meeting of the World Lung Cancer Conference in September, 2007, there were two studies presented evaluating Camptosar (irinotecan)-platinum regimens in small cell lung cancer (SCLC).
Vandetanib Plus Taxotere® Effective for Previously Treated NSCLC (11/2/2007)
Researchers involved in an international study have reported that the addition of vandetanib to Taxotere® improves progression-free survival in patients with previously treated non-small cell lung cancer (NSCLC). The details of this study appeared in the September 20, 2007 issue of the Journal of Clinical Oncology.
Possible Progress in Vaccine Treatment of Non-Small Cell Lung Cancer (NSCLC) (11/1/2007)
At the 12th World Conference on Lung Cancer in September, 2007 two studies were presented which suggest that vaccine therapies may be effective in patients with early stage non-small cell lung cancer (NSCLC).
Avastin® Added Safely to Paraplatin and Camptosar for Small Cell Lung Cancer (11/1/2007)
Researchers from the Sarah Cannon Research Institute determined that Avastin (bevacizumab) could be safely added to the regimen of Paraplatin (carboplatin) and Camptosar (irinotecan) in patients with extensive stage small cell lung cancer (SCLC).[1] The details of this study were presented at the 12th World Conference on Lung Cancer in September, 2007.
Avastin® Plus Chemotherapy for Non-Squamous NSCLC Poorly Tolerated in the Elderly (10/31/2007)
Researchers affiliated with Eastern Cooperative Oncology Group (ECOG) 4599 study reported that the addition of Avastin (bevacizumab) to chemotherapy in patients 70 years or older with advanced NSCLC did not improve survival due to increased toxicities. The details of this study were presented at the 12th World Conference on Lung Cancer in September, 2007.
Partial Hold on Telcyta® Development Removed (10/26/2007)
The United States Food and Drug Administration (FDA) has removed the partial hold it had placed on the clinical development of Telik, Inc’s investigative small molecule Telcyta (canfosfamide HCL, TLK286).
Avastin® with Chemotherapy or Tarceva® Superior to Chemotherapy Alone in NSCLC (10/24/2007)
A multi-institution US study has determined the addition of Avastin (bevacizumab) to Tarceva (erlotinib) or to chemotherapy improves survival compared with chemotherapy alone in the treatment of recurrent non–small cell lung cancer (NSCLC). The details of this study appeared in an early on-line publication in the Journalof Clinical Oncology on October 1, 2007.
Autoantibodies to Cancer Associated Antigens May Help Detect Early Lung Cancer (10/22/2007)
Researchers from the UK and Germany have reported that an autoantibody response to one or more tumor associated antigens could provide a specific test for the detection of early lung cancer. The details of this study appeared in an early on-line publication in Thorax on October 11, 2007.
Thalomid® May not Improve Outcomes of Patients with Small-Cell Lung Cancer (SCLC) (10/22/2007)
Researchers from the UK have reported that the addition of Thalomid to etoposide plus Paraplatin (carboplatin) did not improve outcomes of patients with advanced small cell lung cancer SCLC). The details of this randomized trial were presented at the Presidential Symposium of the 12th World Conference on Lung Cancer in Seoul, Korea, September 2-6, 2007.
Oral Hycamtin® (topotecan) Approved for Relapsed Small Cell Lung Cancer (10/16/2007)
The United States Food and Drug Administration (FDA) has approved an oral formulation of Hycamtin capsules for the treatment of relapsed small cell lung cancer (SCLC). This approval will allow patients to be treated at home.
Alimta®/Platinol Less Toxic than Gemzar/Platinol for Advanced NSCLC (10/16/2007)
An international study has concluded that Alimta (pemetrexed) plus Platinol (cisplatin) is less toxic and equally effective as the standard combination of Gemzar® plus Platinol for treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). The details of this study were presented at the 12th World Conference on Lung Cancer in Vancouver, British Columbia, September 2-6, 2007 and at ECCO 14 – the European Cancer Conference in Barcelona, Spain, September 23-27, 2007.
Iressa® Active in the Treatment of Adenocarcinoma of the Esophagus (10/11/2007)
Researchers from the UK have reported that Iressa (gefitinib) is an active and well tolerated treatment for adenocarcinoma of the esophagus. The details of this study appeared in the October 1, 2007 issue of Clinical Cancer Research.
Students Report High Level of Exposure to Secondhand Smoke (10/3/2007)
According to an international survey of students between the ages of 13 and 15 years, almost half of the nonsmokers reported that they were exposed to secondhand smoke at home and a similar number reported that they were exposed to secondhand smoke outside of the home. These results were published in the Morbidity and Mortality Weekly Report.
Alimta® and Platinum Equally Effective and Less Toxic than Gemzar®-Platinum for Advanced NSCLC (9/21/2007)
According to results presented at the 2007 International Association for the Study of Lung Cancer (IASLC), initial therapy with Alimta® (pemetrexed) combined with a platinum agent (Platinol® [cisplatin] or Paraplatin® [carboplatin]) provides the same survival as Gemzar® (gemcitabine), but with less side effects, for patients with advanced non–small cell lung cancer (NSCLC).
Addition of Gemzar® to Taxotere® Improves Survival as Initial Therapy in Non–Small Cell Lung Cancer (9/19/2007)
Researchers from Greece have reported that the addition of Gemzar® (gemcitabine) to Taxotere® (docetaxel) improves survival compared with Taxotere only when used as initial therapy in patients with advanced non–small cell lung cancer (NSCLC). The details of this study appeared in an early online publication in Lung Cancer.
CT Lung Cancer Screening Outside a Clinical Trial Not Recommended by ACCP (9/18/2007)
The American College of Chest Physicians (ACCP) has concluded that “no screening modality has shown to alter mortality outcomes” of patients at high risk of lung cancer. They recommend that “individuals undergo screening only when it is administered as a component of a well-designed clinical trial with appropriate human subjects’ precautions.” The details of this study were included in a September 2007 supplement to Chest and are part of the ACCP Evidence-Based Clinical Guidelines (2nd Edition) on Lung Cancer.
Sputum Test May Aid in Detecting Lung Cancer (9/18/2007)
According to results presented at the 2007 International Association for the Study of Lung Cancer (IASLC) conference, genetic markers that can be detected in a patient’s sputum may aid in the screening process for early diagnosis of lung cancer.
Photodynamic Therapy Effective for Patients with Early Central Lung Cancer Not Eligible for Surgery (9/17/2007)
Researchers from the UK have reported that treatment with photodynamic therapy is an effective strategy for patients who have early central lung cancer and are not eligible for surgery. The details of this study appeared in the May 2007 issue of Thorax.
Aranesp® Has No Adverse Effect on Survival or Progression-free Survival when Used to Treat Chemotherapy-induced Anemia in SCLC (9/17/2007)
Researchers involved in Amgen’s Aranesp pharmacovigilance program (the 145 Study) have reported that Aranesp (darbepoetin alfa) has no adverse effect on the outcomes of patients with extensive stage small cell lung cancer (SCLC) receiving platinum-based chemotherapy. The details of this randomized Phase III study were reported at the 2007 World Conference on Lung Cancer.
Further Results Show Improved Survival with Picoplatin for Small Cell Lung Cancer (9/11/2007)
Researchers affiliated with the Picoplatin Small Cell Lung Cancer (SCLC) Study Group have reported that follow-up of a Phase II study presented at the 2007 American Society of Clinical Oncology Meeting (ASCO) showed that picoplatin may improve survival compared to existing therapies in the treatment of patients diagnosed with SCLC who have previously received platinum-based therapies. The details of this study were presented at the 2007 meeting of the International Association for the Study of Lung Cancer (IASLC).
Risk of Arterial Thromboembolic Events Following Avastin® Therapy Defined (9/10/2007)
Researchers involved in 5 randomized trials have reported that treatment of metastatic colorectal cancer, breast cancer, or non–small lung cancer with a combination of Avastin (bevacizumab) and chemotherapy results in a higher risk of arterial thromboembolic events than treatment with chemotherapy alone. These results were published in the August 15, 2007 issue of the Journal of the National Cancer Institute.
Vascular Disrupting Agent, ASA404, Improves Survival for Lung Cancer (8/29/2007)
According to a press release by Antisoma, the small molecule vascular disrupting agent (ASA404) improves anticancer responses and survival for patients with non–small cell lung cancer (NSCLC). Specific data including time to cancer progression and overall survival will be presented at the 2007 World Lung Cancer Conference in Seoul, Korea.
Untreated Stage I Non–Small Cell Lung Cancer is Fatal (8/23/2007)
Researchers from several California institutions have reported that untreated patients with Stage I non–small cell lung cancer (NSCLC) have a median survival time of nine months, with only 6% of patients surviving for five years. They suggest that early detection of lung cancer will not lead to over-treatment of indolent disease. The details of this study appeared in the July 2007 issue of Chest.
Radiation to the Brain Should Become Standard Therapy for Extensive-Disease Small Cell Lung Cancer (8/21/2007)
Researchers affiliated with the EORTC Radiation Oncology Group and Lung Cancer Group have reported that prophylactic cranial radiation following treatment with chemotherapy should now become a standard treatment option for patients with extensive-disease small cell lung cancer (SCLC). The details of this randomized trial were published in the August 16, 2007 issue of the New England Journal of Medicine. This study had previously been presented at the 2007 meeting of the American Society of Clinical Oncology.
Ixabepilone Evaluated in Non-Small Cell Lung Cancer (NSCLC), Bladder Cancer and Prostate Cancer (8/17/2007)
There have been three recent clinical trials evaluating ixabepilone, in NSCLC, bladder cancer and prostate cancer. Ixabepilone is an epothilone B analog that binds to microtubules and results in microtubule stabilization and mitotic arrest. There have been several recent publications demonstrating significant activity for single agent ixabepilone in patients with metastatic breast cancer.
Intraperitoneal Catumaxomab Palliates Ascites from Ovarian Cancer (8/16/2007)
Researchers from Germany have reported significant activity for the intraperitoneal infusion of the monoclonal antibody, catumaxomab (Removab®), in women with malignant ascites due to refractory ovarian cancer. The details of this Phase I/II study appeared in the July, 2007 issue of Clinical Cancer Research.
Chemotherapy plus Surgery Improves Outcomes in Non–Small Cell Lung Cancer (8/10/2007)
According to a combined analysis of previously published studies, pre-operative chemotherapy improves survival among patients with non–small cell lung cancer (NSCLC). These results were published in the Cochrane Database of Systematic Reviews.
Little Evidence That Lycopene Reduces Cancer Risk (7/23/2007)
According to a review conducted by the U.S. Food and Drug Administration (FDA), there is “no credible evidence” that lycopene reduces the risk of cancers such as prostate cancer, and “very limited evidence” that tomato consumption reduces risk. The review was published in the July 10,2007 issue of the Journal of the National Cancer Institute.
Fruit and Vegetable Consumption Decreases Lung Cancer Incidence in Smokers (7/13/2007)
European researchers have determined that a high intake of fruits and vegetables significantly lowers the incidence of lung cancer in smokers. The details of this study appeared in the September, 2007 issue of the International Journal of Cancer.
Tarceva® May Be Effective in Patients with NSCLC Progressing after Responding to Iressa® (7/11/2007)
Researchers from South Korea have reported that Tarceva® (erlotinib) may be effective in patients with stable non–small cell lung cancer (NSCLC) after treatment with Iressa® (gefitinib). The details of this study were reported in the June 20, 2007 issue of the Journal of Clinical Oncology.
Test Predicts Response of NSCLC to Iressa® and Tarceva® (7/10/2007)
Researchers from Vanderbilt University have reported that a mass spectrometry test of serum prior to treatment can predict response of patients with non-small cell lung cancer (NSCLC) to Tarceva® (erlotinib) and Iressa® (gefitinib).This study was published in the June, 2007 issue of the Journal of the National Cancer Institute.
Surgeon General Reports on Health Consequences of Secondhand Smoke (7/5/2007)
The 2006 Report of the Surgeon General on the health consequences of involuntary exposure to tobacco smoke was published in the June 2007 issue of the American Journal of Preventive Medicine. A copy of the complete report can be accessed on the US Department of Health and Welfare website.
Addition of Gliadel® Wafer to Surgery and Radiation Effective for Brain Metastasis (6/27/2007)
Researchers involved in a multicenter trial have reported that the addition of Gliadel® Wafer (carmustine polymer wafer) to surgery plus external beam radiotherapy is a safe and effective regimen for patients with single brain metastasis. The details of this study appeared in the June 15, 2007 issue of Clinical Cancer Research.
Stereotactic Single-Dose Radiotherapy Effective for Stage I-II Non-Small Cell Lung Cancer (NSCLC) (6/22/2007)
Researchers from Germany have reported that single-dose stereotactic radiotherapy is associated with a 69% 36 month local control rate in patients with stage I-II non-small cell lung cancer (NSCLC). The details of this study appeared in the July, 2007 issue of Cancer.
Addition of Avastin® to Gemzar®/Platinol® Combination Improves Progression-free Survival in NSCLC (6/22/2007)
Researchers affiliated with an international trial (BO 17704) have reported that the addition of Avastin® (bevacizumab) to the chemotherapy combination including Gemzar® (gemcitabine) plus Platinol® (cisplatin) improves progression-free survival among patients with non-squamous, non–small cell lung cancer (NSCLC). The details of this study were presented as a late-breaking abstract at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Axitinib, an Oral Tyrosine Kinase Inhibitor, has Activity in NSCLC (6/15/2007)
Researchers involved in a multicenter trial have reported that Axitinib (AG-01376) has significant single agent activity in patients with advanced non-small cell lung cancer(NSCLC). The details of this Phase II trial were presented at the 2007 meeting of the American Society of Clinical Oncology.
Prophylactic Cranial Radiation Improves Survival in Extensive Small-Cell Lung Cancer (6/5/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), prophylactic cranial radiation following treatment with chemotherapy doubles survival at one year and reduces the risk of developing brain metastasis among patients with extensive-disease small cell lung cancer (SCLC).
Oral and Intravenous Hycamtin® Equally Effective for Small Cell Lung Cancer (5/24/2007)
Researchers involved in an international study have confirmed that the oral form of Hycamtin (topotecan) is as effective as the intravenous form for the second line palliative treatment of small cell lung cancer (SCLC). The details of this randomized trial appeared in the May 20, 2007 issue of the Journal of Clinical Oncology.
NDA Accepted for Xcytrin (5/7/2007)
The United States Food and Drug Administration (FDA) has accepted the new drug application (NDA) submitted for Pharmacyclics’ new agent Xcytrin (motexafin gadolinium). Pharmacyclics is seeking approval for the use of Xcytrin in combination with radiation therapy for the treatment of patients with non-small cell lung cancer (NSCLC) and brain metastases.
Xyotax Granted Fast-Track Status (5/3/2007)
Cell Therapeutics has been granted fast-track status for their agent Xyotax (paclitaxel poliglumex) for the initial treatment of women with advanced non-small cell lung cancer (NSCLC) who have a poor performance status.
Response Rate to Chemotherapy for NSCLC not Affected by Ethyol® (5/2/2007)
Researchers from the MD Anderson Cancer Center have reported that response rates for locally advanced non-small-cell lung cancer (NSCLC) to chemotherapy are not affected by Ethyol® (amifostine) cytoprotection. The details of this study appeared in an early on-line publication in the International Journal of RadiationOncology* Biology* Physics on February 6, 2007.
Proton Beam Therapy Confirmed Effective for Stage I NSCLC (4/30/2007)
Researchers from Japan have reported a 2 year survival of 74% and a cause-specific survival of 86% in patients with stage I non-small cell lung cancer. The details of this study appeared in an early on-line publication in the InternationalJournal Radiation Oncology* Biology* Physics on March 20, 2007.
Epoetin Alfa May Decrease Survival in Anemic Patients with NSCLC (3/26/2007)
Researchers affiliated with the Ontario Oncology Group have reported that anemic patients with non-small cell lung cancer (NSCLC) randomly allocated to receive epoetin alfa (Eprex®, Procrit®) for disease-related anemia had a shorter median survival than patients receiving a placebo. The details of this study appeared in the March 20, 2007 issue of the Journal of Clinical Oncology.
Radiotherapy May be Best Choice for Selected Patients with Stage IIIA NSCLC (3/26/2007)
Researchers affiliated with the European Organisation for Research and Treatment of Cancer (EORTC)-Lung Cancer Group have reported that patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC) who respond to chemotherapy have equivalent survivals following radiotherapy or surgery. The details of this study appeared in the March 21, 2007 issue of the Journal of the National Cancer Institute.
Workplace Exposure to Second-Hand Tobacco Smoke Associated with Increased Lung Cancer Risk (3/15/2007)
An international multi-center study has confirmed that exposure to second-hand tobacco smoke increases the risk of developing lung cancer. The details of this study appeared in the March 1, 2007 issue of the American Journal of Public Health.
Further Data Links Family History of Lung Cancer to Increased Risk of Cancers Among Never-Smokers (2/28/2007)
Researchers from the M.D. Anderson Cancer Center have reported that a family history of lung cancer significantly increases risk of developing lung and other cancers in non-smokers.
Two Genes Predict Survival Following Surgery in Early Non–Small Cell Lung Cancer (2/26/2007)
Researchers from the H. Lee Moffitt Cancer Center have reported that expression of two proteins, RRM1 and ERCC1, can help predict which patients with early-stage non–small cell lung cancer (NSCLC) will have a good survival after surgery.
Carbon Ion Beam Therapy Effective for Stage I Non-Small Cell Lung Cancer (2/23/2007)
Researchers from Japan have reported that treatment of stage I non-small cell lung cancers (NSCLC) with carbon ion beam therapy results in a 95% local control rate with minimal side effects.
High Intake of Vegetables and Fruit Reduces Risk of Lung Cancer in China (2/22/2007)
A Chinese study has shown that a high intake of vegetables and fruit drastically reduces the risk of lung cancer. The reduced risk is particularly evident in smokers but is also apparent in non-smokers.
Non-Smoking Women at Higher Risk of Lung Cancer Than Non-Smoking Men (2/14/2007)
An international group has reported that women who have never smoked are at a higher risk of developing lung cancer than men who have never smoked.
Five-Gene Signature Predicts Outcome of Patients with NSCLC (2/5/2007)
Researchers from Taiwan have reported that a five-gene signature is closely associated with relapse-free and overall survival of patients with non-small cell lung cancer (NSCLC).
Dose-Intensive Chemotherapy with Stem Cell and Neupogen® Support Improves Survival in SCLC (2/5/2007)
A randomized phase III study that intensified doses of ICE (ifosfamide, carboplatin, and etoposide) administered with autologous stem cell and Neupogen (filgrastim) support improves median survival compared to standard doses of ICE for the treatment of small cell lung cancer (SCLC).
Lobectomy May Improve Survival Compared to Wedge Resection in Stage IA Lung Cancers (2/1/2007)
Researchers from three tertiary medical centers have reported that patients with stage IA lung cancers have a better survival following lobectomy than following wedge resection.
Monitoring Bronchial Dysplasia Results in Early Diagnosis of Lung Cancer (2/1/2007)
Researchers from the United Kingdom have reported that patients with bronchial dysplasia may have improved chances of a cure if they are regularly screened and monitored for the development of lung cancer.
Special Protocol Assessment Filed for Xyotax (2/1/2007)
Cell Therapeutics has filed with the United States Food and Drug Administration (FDA) for a special protocol assessment (SPA) for the design of a phase III trial evaluating their investigative agent Xyotax.
Abraxane®/Paraplatin® Effective for Recurrent NSCLC (1/24/2007)
The combination of Abraxane (albumin bound paclitaxel) and Paraplatin (carboplatin) appears effective for the treatment of recurrent NSCLC among patients with stage IIIB/IV non-small cell lung cancer (NSCLC). These results were presented at the 2006 annual meeting of the Chemotherapy Foundation Symposium.
Abraxane®/Avastin® Promising as Initial Therapy for Advanced Non-Small Cell Lung Cancer (1/24/2007)
The combination of Abraxane (albumin bound paclitaxel) and Paraplatin® (carboplatin) and Avastin (bevacizumab) provides responses or disease stabilization in over 75% of patients with chemotherapy-naïve, advanced non-small cell lung cancer (NSCLC). These results were presented at the 2006 annual Chemotherapy Foundation Symposium.
Avastin® Improves Survival in Advanced Non-Small Cell Lung Cancer (1/12/2007)
Researchers affiliated with the Eastern Cooperative Oncology Group (ECOG) have reported that the addition of Avastin (bevacizumab) to Taxol® (paclitaxel) and Paraplatin® (carboplatin) improves survival in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).
Physical Activity May Reduce Lung Cancer Risk in Female Smokers (1/10/2007)
Researchers from the University of Minnesota and the University of Pennsylvania have reported that physical activity may reduce the risk of developing lung cancer in current and former smokers.
Amrubicin Shows Promise in Relapsed or Refractory Small Cell Lung Cancer (12/7/2006)
Researchers from Japan have reported at 50% response rate following treatment with the new synthetic anthracycline amrubicin in patients with refractory or relapsed small cell lung cancer (SCLC).
Calypso® 4D Localization System May Improve Efficacy of External Beam Radiotherapy (12/1/2006)
At the 2006 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in November there were 10 abstracts presented that describe a new system for measuring and monitoring organ motion in real time during external beam radiotherapy (EBRT).
Fractionated Camptosar® Plus Paraplatin® Well Tolerated in Patients with Extensive Disease-SCLC (12/1/2006)
Researchers from Korea have reported that a regimen of fractionated Camptosar (irinotecan) plus Paraplatin (carboplatin) is a well tolerated regimen for patients with previously untreated extensive disease-small cell lung cancer ED-SCLC.
Role of Nexavar® in NSCLC Reviewed (11/30/2006)
Dr. Corey Langer from the Fox Chase Cancer Center reviewed the status of Nexavar (sorafenib) for the treatment of non-small cell lung cancer (NSCLC) at the Chemotherapy Foundation Symposium XXIV in New York in November 2006.
Low Hematologic Toxicity Rate for Gemzar® and Ellence® in Advanced NSCLC (11/28/2006)
Researchers from Italy have reported that the combination of Gemzar (gemcitabine) and Ellence (oxaliplatin) (GEMOX) has a good toxicity profile and equivalent effectiveness to other non-Platinol® (cisplatin)-based regimens for initial therapy of patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
Concurrent Chemotherapy, Twice-Daily Radiation and Consolidation Chemotherapy Promising for Limited Small Cell Lung Cancer (11/27/2006)
Researchers from Japan have reported that concurrent twice-daily radiotherapy and standard VePesid® (etoposide) plus Platinol® (cisplatin) followed by consolidation with Camptosar® (irinotecan) plus Platinol may improve outcomes of patients with limited-disease small cell lung cancer (LD-SCLC).
Further Evidence for Activity of Gemzar® and Ellence® in Advanced NSCLC (11/21/2006)
Researchers from Greece have reported palliative benefit in over 40% of patients with non-small cell lung cancer (NSCLC) who have failed platinum and taxane therapies with a regimen of Gemzar (gemcitabine) and Ellence (oxaliplatin) (GEMOX).
Further Data Indicates Hereditary Link to Lung Cancer (11/20/2006)
Researchers from the United Kingdom have reported that individuals who have family members diagnosed with lung cancer, particularly those whose family members were diagnosed at an early age, are at a significantly increased risk of developing lung cancer themselves.
Split Dose Paraplatin® Decreases Severe Thrombocytopenia in Patients with NSCLC (11/1/2006)
German researchers have reported that split-dose Paraplatin (carboplatin) decreases the incidence of severe thrombocytopenia from 51% to 35% compared to a single dose regimen when combined with Gemzar® (gemcitabine) for treatment of patients with advanced non-small cell lung cancer (NSCLC).
Iressa® Active and Well Tolerated in Advanced NSCLC Patients With EGFR Mutations (10/30/2006)
Researchers from Hokkaido, Japan have reported that 75% of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations responded to Iressa (gefitinib).
Annual Spiral CT Screening May Detect Curable Lung Cancer (10/27/2006)
Researchers associated with the International Early Lung Cancer Action Program have reported that the 10-year survival of patients with CT screen-detected stage I lung cancer was 88% for all patients and 92% for those undergoing surgery within one month of diagnosis.
Taxotere® Consolidation May Improve Outcomes for Stage IIIB NSCLC (10/24/2006)
Researchers affiliated with the Southwest Oncology Group (SWOG) have reported that the Taxotere® (docetaxel) consolidation following concurrent Platinol® (cisplatin/VePesid® (etoposide) and thoracic radiation therapy may improve outcomes in patients with Stage IIIB non–small cell lung cancer (NSCLC).
Alimta® Safe and Active in Small Cell Lung Cancer (10/24/2006)
Researchers involved in a multicenter randomized phase II trial have reported that Alimta® (pemetrexed) and either Platinol® (cisplatin) or Paraplatin® (carboplatin) provides a safe and effective treatment for newly diagnosed patients with extensive small cell lung cancer (SCLC).
Gene Modified Allogeneic Tumor Cell Vaccine Active in NSCLC (10/12/2006)
Researchers from the Medical Research Center/Texas Oncology Professional Associates and Baylor University have reported that belagenpumatucel-L, a nonviral allogeneic tumor cell vaccine is well tolerated, produced clinical responses and may improve survival in patients with non-small cell lung cancer.
Adjuvant Platinol®/Navelbine® Improves Survival in NSCLC (10/11/2006)
Researchers affiliated with the Late Adjuvant Cisplatin Evaluation (LACE vinorelbine project) have reported that adjuvant Platinol® (cisplatin) plus Navelbine® (vinorelbine) improves survival among patients with completely resected non–small cell lung cancer (NSCLC).
NCI Announces New Phase I/II Study of Vaccine for NSCLC (10/9/2006)
The Metabolism Branch of the National Cancer Institute (NCI) in Bethesda, Md., has announced that it is conducting a Phase I/II clinical trial to test the efficacy of using α (1,3) galactosyltransferase expressing allogeneic tumor cells in patients with refractory or recurrent non-small cell lung cancer (NSCLC).
Survival Benefit From Adjuvant Chemotherapy for Stage I But Not Stage II-IIIA NSCLC (10/5/2006)
Japanese researchers have reported that one year of adjuvant therapy with oral UFT (uracil and tegafur) improves 8-year survival for stage I non-small cell lung cancer (NSCLC).
3D Radiotherapy Improves Outcome of Inoperable Stage I NSCLC (10/3/2006)
Researchers from the M.D. Anderson Cancer Center have reported that patients with inoperable stage I non-small cell lung cancer (NSCLC) survived longer following 3D radiotherapy than following 2D radiotherapy.
Monoclonal Antibody Linked to Doxorubicin Safe and Possibly Effective for NSCLC (9/29/2006)
Researchers involved in a multicenter trial have reported that an immunoconjugate, SGN-15, plus Taxotere® may be superior to Taxotere® alone for treatment of refractory NSCLC.
Chemotherapy Plus Radiation Superior to Radiation Alone Following Initial Chemotherapy for Lung Cancer (9/26/2006)
Researchers from Germany have reported that chemoradiotherapy provides superior progression-free and overall survival compared to radiation therapy alone following initial chemotherapy for the treatment of inoperable Stage IIIA or IIIB non–small cell lung cancer (NSCLC).
FISH Plus Cytology Optimal for Detecting Lung Cancer Bronchoscopy Specimens (9/21/2006)
Researchers from the Mayo Clinic have reported that fluorescence in situ hybridization (FISH) is more accurate than cytology in detecting lung cancer in bronchoscopy specimens, but both tests together are even more accurate.
Scarring and Pulmonary Fibrosis on Screening Chest X-Rays Associated with Increase Risk of Lung Cancer (9/13/2006)
Researchers affiliated with the Prostate, Lung, Colorectal and Ovarian Screening (PLICO) Trial have reported that persons with scarring and pulmonary fibrosis on chest X-rays performed as part of a screening program is associated with a two-fold increase in the incidence of lung cancer.
ERCC1 Predicts Responses to Chemotherapy in Early Lung Cancer (9/11/2006)
Researchers from Europe affiliated with the International Adjuvant Lung Cancer Biology study have reported that the excision repair cross-complementation group 1 (ERCC1) can identify patients who will achieve a benefit from Platinol® (cisplatin)-based adjuvant chemotherapy for the treatment of early non-small cell lung cancer (NSCLC).
Final Results of Adjuvant Chemotherapy Versus Observation for Resected NSCLC Published (8/28/2006)
Researchers affiliated with the Adjuvant Navelbine International Trialist Association (ANITA) have published the final results of a randomized trial evaluating adjuvant Navelbine® (vinorelbine)/Platinol® (cisplatin) have reported that adjuvant chemotherapy for patients with stage II-IIIA resected non-small cell lung cancer (NSCLC) improved survival by 8.6% at 7 years.
Eloxatin® and Taxotere® Safe and Effective Palliation for Metastatic NSCLC (8/22/2006)
Researchers from the University of Miami have reported that the combination of Eloxatin (oxaliplatin) and Taxotere (docetaxel) is a well tolerated and active combination for the treatment of advanced and metastatic non-small cell lung cancer.
Gene Expression Profile Predicts Survival in Early Stage Lung Cancer (8/11/2006)
Researchers from Duke University have reported that a lung metagene model accurately predicts the survival of patients with IA non-small cell lung cancer (NSCLC).
Surgical Removal May Improve Survival for All Stages of Lung Cancer (8/10/2006)
Researchers from Norway have reported that surgical removal of lung cancer may improve outcomes of patients with lung cancer, including those with locally advanced or metastatic disease.
Paraplatin®, Camptosar® Supported by Neupogen® Well Tolerated in Elderly with Small Cell Lung Cancer (8/4/2006)
Researchers from Japan have reported that a regimen of Paraplatin (carboplatin) and Camptosar (irinotecan) supported by Neupogen was effective and well tolerated in elderly patients with small cell lung cancer (SCLC).
Taxotere® (Docetaxel)-Platinum Combinations Improve Quality of Life in Patients with Advanced NSCLC. (8/4/2006)
Researchers have reported that the chemotherapy combinations of Taxotere and Platinol® (cisplatin) or Taxotere and Paraplatin® (carboplatin) results in better quality of life (QOL) assessments in patients with advanced non-small cell lung cancer than the combination of Navelbine® (vinorelbine) and Platinol.
Taxotere® (Docetaxel) May Be Superior to Navelbine® (Vinolrelbine) for Elderly with Advanced NSCLC (8/2/2006)
Researchers from Japan have reported that treatment with single-agent Taxotere provides superior progression-free survival and improves symptoms caused by cancer better than treatment with single-agent Navelbine for elderly patients with non–small cell lung cancer (NSCLC).
Thermal Ablation Plus Radiation Therapy May Improve Survival in Early Lung Cancer (8/1/2006)
Researchers from Brown University have reported that the combination of radiofrequency ablation (RFA) or microwave ablation plus radiation therapy may improve survival compared with either modality alone in the treatment of inoperable, early lung cancer.
Abraxane® Active for Initial Therapy of Advanced Non-Small Cell Lung Cancer (7/17/2006)
Researchers from the Medical University of South Carolina have reported that single agent Abraxane (albumin bound paclitaxel, ABI-007) is well tolerated and produces significant responses in patients with previously un-treated non-small cell lung cancer (NSCLC).
Iressa® Effective in Initial Treatment of Subset of Lung Cancer Patients (7/16/2006)
Japanese researchers have reported a 75% response rate following initial therapy with Iressa (gefitinib) in patients with advanced non-small cell lung cancer (NSCLC) that have EGFR gene mutations.
Women May Have Increased Susceptibility to Tobacco Carcinogens Compared to Men (7/12/2006)
Researchers affiliated with the International Early Lung Cancer Action Program have reported that women may have increased susceptibility to tobacco carcinogens but have a better survival after the diagnosis of lung cancer when compared to men.
Avastin®/Tarceva® Effective Alternative to Chemotherapy in Recurrent Non-Small Cell Lung Cancer (7/10/2006)
According to results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), the treatment combination consisting of the targeted agents Avastin (bevacizumab) and Tarceva (erlotinib) may provide an effective and better tolerated treatment option compared to chemotherapy for non-small cell lung cancer (NSCLC) patients who have received prior therapies.
Velcade® Plus Gemzar®/Paraplatin® Highly Active in Advanced NSCLC (7/10/2006)
According to results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), the treatment combination consisting of Velcade (bortezomib) plus Gemzar (gemcitabine) plus Paraplatin (carboplatin) provides impressive survival in patients with advanced non-small cell lung cancer.
Oral Hycamtin® May Offer Oral Therapy for Recurrent Non–Small Cell Lung Cancer (6/30/2006)
Researchers from Europe, South Africa and Canada have reported that oral Hycamtin (topotecan) and intravenous Taxotere® (docetaxel) are of equal benefit for the treatment recurrent non–small cell lung cancer (NSCLC). The details of this phase III randomized trial appeared in the June 20, 2006, issue of the Journal of Clinical Oncology.
Addition of Thalomid® to Chemotherapy Improves Survival in Small Cell Lung Cancer (6/30/2006)
Researchers from France have reported that the addition of Thalomid (thalidomide) to chemotherapy improves survival in patients with extensive small cell lung cancer (SCLC). The details of this study were presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Ga.
Sutent® Shows Promise in Advanced Non-Small Cell Lung Cancer (6/13/2006)
According to preliminary phase II results presented at the 2006 annual meeting of the American Society of Clinical Oncology, Sutent® (sunitinib) resulted in a partial response in 9.5% of patients with previously-treated, advanced non-small cell lung cancer (NSCLC), and stable disease in 41% of patients.
Updated Results from CALGB 9633 Show No Benefit of Adjuvant Chemotherapy in Stage IB Non-Small Cell Lung Cancer (6/12/2006)
Results described by a discussant as “practice changing” were presented at a lung cancer session of the 2006 annual meeting of the American Society of Clinical Oncology (ASCO). The Cancer and Leukemia Group B (CALGB) protocol 9633, which previously reported a survival benefit of adjuvant chemotherapy among patients with resected stage IB non-small cell lung cancer (NSCLC), reported that updated analyses indicate no evidence of an overall survival benefit.
Additional Evidence of Abraxane™ Activity in Advanced Non-Small Cell Lung Cancer (6/8/2006)
According to the results of a phase II clinical trial presented at the annual meeting of the American Society of Clinical Oncology, Abraxane™ (albumin-bound paclitaxel) followed by Paraplatin® (carboplatin) resulted in a 29% response rate among previously untreated patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC).
Abraxane™ Shows Single-Agent Activity in Stage IV Non-Small Cell Lung Cancer (6/8/2006)
According to the results of a phase I/II trial presented at the 2006 meeting of the American Society of Clinical Oncology (ASCO), Abraxane™ (albumin-bound paclitaxel) produces a response rate of 30% in chemotherapy-naïve patients with stage IV non-small cell lung cancer (NSCLC).
Combination of Abraxane™ and Paraplatin® Active in the Treatment of Advanced Non-Small Cell Lung Cancer (6/5/2006)
According to the results of a phase II clinical trial presented at the 2006 annual meeting of the American Society of Clinical Oncology, the combination of Abraxane™ (albumin-bound paclitaxel) and Paraplatin® (carboplatin) is tolerable and active in the treatment of newly-diagnosed advanced non-small cell lung cancer (NSCLC).
Primary Care Physicians Tend to Not Understand Role of Chemotherapy in Lung Cancer Patients (6/5/2006)
Only 11% of primary care physicians believe that patients with early-stage lung cancer can achieve benefit from treatment with chemotherapy, resulting in potentially suboptimal referral rates of these patients to oncologists. These results were recently reported at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO).
Immediate Taxotere® After Gemzar® and Paraplatin® Induction Therapy Does Not Significantly Increase Toxicity in NSCLC (6/5/2006)
According to the interim results of a phase III clinical trial presented at the 2006 American Society of Clinical Oncology meeting, patients with advanced non-small cell lung cancer (NSCLC) who received Taxotere® (docetaxel) immediately after induction therapy with Gemzar® (gemcitabine) and Paraplatin® (carboplatin) experienced a similar rate of grade 3 or 4 adverse events as patients who received Taxotere only at cancer progression.
Risk Factors for Non-Smoking Related Lung Cancer Reported (5/22/2006)
Researchers from M.D. Anderson Cancer Center have reported that exposure to second-hand tobacco smoke, dusts and family history of early cancer is associated with an increased risk of non-smoking related lung cancer. Researchers from the same institution have also reported that first-degree relatives of lung cancer patients who have never smoked are at an increase risk of developing any cancer.
No Increase in Lung Cancer in Non-Smokers in Past 40 Years (5/22/2006)
Researchers from the American Cancer Society and the University of California at San Diego have reported that the incidence of lung cancer in non-smokers has remained relatively constant at approximately 15 per 100,000 for men and 12 per 100,000 for women since 1959.
Epoetin Alfa May Improve Survival After Chemoradiotherapy for Esophageal Cancer (5/10/2006)
Researchers from Germany have reported a follow-up study of a previous trial showing that the administration of epoetin alfa to maintain hemoglobin levels between 12 and 14 g/dL improves overall survival and locoregional control of stage III esophageal cancer receiving chemotherapy and radiation therapy.
Many Abnormalities on CT Screening for Lung Cancer Do Not Require Biopsies (5/5/2006)
Researchers from Cornell University have reported that many abnormalities detected on annual computerized tomography (CT) screening scans for lung cancer clear with observation with or without antibiotics. Only persistent or growing nodules required further evaluation. The details of this report appeared in the April 2006 issue of Chest.
Radiation Therapy Effective for Early NSCLC in the Elderly (5/3/2006)
Researchers from Spain have reported that radiation therapy alone appears to be effective and well-tolerated in elderly patients with early stage non-small cell lung cancer (NSCLC). These results were published in the journal Lung Cancer.
Advexin® is a Promising Vaccine for NSCLC and Esophageal Cancer (4/27/2006)
Researchers from Japan have reported that repeated intra-tumor injections of the vaccine Advexin (Ad5CMV-p53) produces clinical responses in patients with advanced non-small cell lung cancer.
Sequential Two Drug Combinations for Advanced NSCLC Promising (4/19/2006)
Researchers from Greece have reported that the sequential administration of Navelbine® (vinorelbine) and Platinol® (cisplatin) followed by Taxotere® (docetaxel) and Gemzar® (gemcitabine) is a promising approach to palliative therapy for patients with stage IIIB and IV non-small cell lung cancer (NSCLC).
Maintenance Therapy May Be of Benefit in Advanced NSCLC (4/13/2006)
Researchers from Europe have concluded that maintenance Gemzar® (gemcitabine) prolongs time to progression (TTP) in patients with stage IIIB and IV non-small cell lung cancer receiving induction therapy with Platinol® (cisplatin) and Gemzar.
Tomudex® Plus Platinol® and Platinol Alone Therapies Both Reduce Dyspnea in Patients With Mesothelioma (3/22/2006)
Researchers affiliated with the European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Group and the National Cancer Institute of Canada have reported that the combination of Tomudex (raltitrexed) and Platinol® (cisplatin) or Platinol alone decrease dyspnea in patients with malignant pleural mesothelioma (MPM).
Radiofrequency Ablation and Radiotherapy Combined for Treatment of Medically Inoperable Stage I NSCLC (3/16/2006)
Researchers from Brown Medical School have reported that the combined use of radiofrequency ablation and radiotherapy was an effective method of treating patients with medically inoperable stage I non-small cell lung cancer.
Small Primary or Metastatic Lung Cancers Treated Successfully with Single-Fraction Stereotactic Radiation Therapy (3/15/2006)
Researchers from Japan have reported that small peripheral primary or metastatic lung cancers can be treated successfully with a single dose of radiation therapy delivered by stereotactic techniques and a novel technique of irradiation only during the expiratory phase of respiration.
Shorter Duration of Treatment Improves Survival with Small-Cell Lung Cancer (3/13/2006)
Researchers from Belgium have reported that a shorter treatment interval is associated with an improved survival of patients with limited-disease small-cell lung cancer (SCLC).
Computed Tomography Screening for Lung Cancer Detects Early Disease (3/1/2006)
Researchers affiliated with the International Early Lung Cancer Action Program Investigators have reported that Computed Tomography (CT) screening detects a higher percentage of early stage lung cancer than observed in a non-screened population.
Gemzar® May Improve Results of Taxol®/Paraplatin® Regimen for Non-Small Cell Lung Cancer (2/9/2006)
Researchers from Italy have reported that the addition Gemzar® (gemcitabine) to Taxol (paclitaxel)/Paraplatin (carboplatin) improves survival of patients with advanced (stage IIIB and IV) non-small cell lung cancer (NSCLC).
Nitroglycerin May Enhance Chemotherapy for Non-Small Cell Lung Cancer (2/6/2006)
Researchers from Japan have reported that the use of nitroglycerin combined with Navelbine® (vinorelbine) and Platinol® (cisplatin) may improve response rates and time to tumor progression in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
Dogs Put Their Noses to Work in the Fight Against Cancer (2/2/2006)
Researchers from Pine Street Foundation in San Anselmo, California, have reported that dogs can identify patients with breast or lung cancer based on the smell of their breath.
Lung Cancer Incidence in Smokers Varies Across Ethnic Groups (2/2/2006)
Researchers from the University of Southern California and the University of Hawaii have reported that African Americans and Native Hawaiians appear to be more susceptible to developing smoking induced lung cancer than whites, Japanese Americans, and Latinos.
Stereotactic Hypofractionated Radiotherapy Promising for Lung Cancer (2/1/2006)
Researchers from Sweden have reported promising results of treating stage I non-small cell lung cancer (NSCLC) with three fractions of 15 Gy given over one week rather than smaller daily doses spread over a longer period of time.
Chinese Herbal Medicine May Increase Effectiveness of Platinum-Based Chemotherapy for Lung Cancer (1/25/2006)
A combined analysis of 34 studies, performed by researchers at the University of California at Berkeley, suggests that Astragalus-based Chinese herbal medicine may increase the effectiveness of platinum-based chemotherapy regimens for advanced non-small cell lung cancer (NSCLC).
Baseline Chest X-Rays Detect Early Lung Cancer (12/23/2005)
Researchers affiliated with the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial found that nearly half of the lung cancers identified on initial screening were stage I compared to the 16% usually observed in clinical practice.
Induction Chemotherapy and Concomitant Chemoradiotherapy Promising in Stage III NSCLC (12/6/2005)
Researchers from Korea have reported that the addition of induction chemotherapy prior to a standard chemoradiotherpy regimen may improve outcomes of patients with inoperable stage IIIA or IIIB non-small cell lung cancer (NSCLC).
Anemia in Lung Cancer Patients Often Undertreated (11/30/2005)
Researchers affiliated with the European Cancer Anaemia Survey (ECAS) have reported that approximately 50% of patients with lung cancer with anemia received appropriate treatment.
Oral Hycamtin® Better than Best Supportive Care for Recurrent Small Cell Lung Cancer (11/14/2005)
Researchers from the United Kingdom have reported that oral Hycamtin (topotecan) improves survival compared to best supportive care as second-line therapy for small cell lung cancer (SCLC).
Abraxane™ Effective for Initial Treatment of Metastatic Non-Small Cell Lung Cancer (11/11/2005)
Researchers from Memorial Sloan-Kettering Cancer Center have reported that Abraxane (albumin-bound paclitaxel) appears to be effective and well tolerated as initial treatment of metastatic non-small cell lung cancer (NSCLC).
Premenopausal Women Have Improved Survival with Xyotax® for Treatment of Non-Small Cell Lung Cancer (11/11/2005)
Retrospective subgroup analysis of two large randomized trials, STELLAR 3 and STELLAR 4, have demonstrated an improved survival with Xyotax compared to other standard chemotherapy regimens in premenopausal women with advanced non-small cell lung cancer.
Neupogen® Plus Antibiotics Decrease Febrile Neutropenia in Small Cell Lung Cancer (11/8/2005)
Researchers from the Netherlands have reported that the addition of Neupogen (granulocyte-colony stimulating factor) to prophylactic antibiotics decreases febrile neutropenia in patients with small cell lung cancer (SCLC) undergoing intensive sequential chemotherapy.
Iressa® Offers Survival Advantage in Select Patients with Refractory Non-Small Cell Lung Cancer (11/4/2005)
Researchers involved in the international multicenter Iressa Survival Evaluation in Lung Cancer (ISEL) trial have reported Iressa (gefitinib) produces a survival advantage in patients with non-small cell lung cancer (NSCLC) of Asian ethnicity and never smokers, but still does not result in an improvement in survival for the overall group.
Dose-Dense Navelbine® and Taxotere® with Neupogen® Support for Non-Small Cell Lung Cancer in Community Oncology Practices (10/21/2005)
Researchers affiliated with 12 community oncology practices have reported that dose-dense Navelbine (vinorelbine) and Taxotere (docetaxel) can be administered safely with Neupogen (filgrastim) support to patients with advanced non-small cell lung cancer (NSCLC) with results similar or better than those achieved with platinum-based regimens administered on conventional schedules.
Vitamin D May Be Associated With Improved Survival of Early Stage Lung Cancer (10/13/2005)
Researchers from the Dana-Farber Cancer Institute have reported improved survivals of patients with early stage non-small cell lung cancer (NSCLC) who had a high intake of vitamin D and were operated on in the summer when compared to similar patients who had a low intake of vitamin D and were operated on in the winter.
Neoadjuvant Chemotherapy and Concurrent Chemoradiotherapy Promising for Stage III Unresectable NSCLC (10/12/2005)
Researchers from the University of Alabama have reported a 3-year survival rate of 45% in patients with stage III non-small cell lung cancer (NSCLC) treated with induction Gemzar® (gemcitabine) and Platinol® (cisplatin) followed by concurrent radiation and chemotherapy with Gemzar and Taxol® (paclitaxel).
High Intake of Phytoestrogens Associated with Lower Risk of Lung Cancer (10/4/2005)
Researchers from M.D. Anderson Cancer Center have reported that diets rich in phytoestrogens are associated with a lower incidence of lung cancer than in individuals consuming diets low in phytoestrotens.
Chemoradiotherapy Promising for Stage I-II Non-Small Cell Lung Cancer (10/3/2005)
Researchers from Yugoslavia have reported a 36% 5-year survival rate for patients with stage I-II non-small cell lung cancer (NSCLC) treated with radiation therapy and concurrent low-dose daily Paraplatin® (carboplatin) and Taxol® (paclitaxel).
Smoking Reduction Reduces Lung Cancer Risk (9/29/2005)
Researchers from Denmark have reported that individuals who smoke 15 or more cigarettes per day can lower their risk of lung cancer by 25% by reducing the number of cigarettes smoked by 50%.
Survival of Stage IIIB Non-Small Cell Lung Cancer May Be Improved With L-BLP25 Vaccine (9/21/2005)
Researchers from Canada and the United Kingdom have reported an improved survival of patients with stage IIIB non-small cell lung cancer (NSCLC) with vaccination to MUC1 protein with L-BLP25 vaccine.
Radiation Improves Average Survival in Early, Unresected Non-Small Cell Lung Cancer (9/16/2005)
Researchers from Mount Sinai School of Medicine and Cornell Medical Center have reported that radiation therapy (RT) improves the average duration of survival for patients with Stage I-II non-small cell lung cancer (NSCLC) who are not able to undergo surgery.
Anemia Prior to Chemotherapy Associated with Poorer Prognosis in Advanced Non-Small Cell Lung Cancer (7/20/2005)
Researchers from France have reported that anemia prior to chemotherapy for advanced non-small cell lung cancer (NSCLC) is associated with a poor prognosis compared to patients without anemia.
Histopathological Features of Lung Cancers Provide No Predictive Value for Response to Adjuvant Chemotherap (7/13/2005)
Researchers from France and Austria have reported that histological features of stage I-III non-small cell lung cancer (NSCLC) do not appear to predict for response to adjuvant chemotherapy.
Quality of Life of Long-Term Lung Cancer Survivors Evaluated (7/12/2005)
Researchers from the Mayo Clinic have reported that the quality of life of long-term survivors of lung cancer shows measurable deficits and decline over time.
Radiofrequency Ablation Reported as Local Therapy for NSCLC (7/8/2005)
Researchers from Italy have reported that radiofrequency ablation appears to be a feasible and safe local therapy for patients with NSCLC who are not candidates for surgery.
Iressa® Produces Survival Advantage in Select Patients with Refractory NSCLC (7/8/2005)
Updated results of the phase III Iressa Survival Evaluation in Lung cancer (ISEL) indicate that Iressa (gefitinib) produces a survival advantage in patients with Asian ethnicity and never smokers, but still does not show an improvement in survival for the overall group.[1]
Adjuvant Navelbine®/Platinol® Improves Survival in the Treatment of Non-Small Cell Lung Cancer (7/7/2005)
Final results of a trial evaluating adjuvant Navelbine (vinorelbine)/Platinol (cisplatin) in the treatment of patients with stage II and IIIA non-small cell lung cancer (NSCLC) showed that the approach provided a significant survival advantage.[1]
Oral Hycamtin® Active in Relapsed Non-Small Cell Lung Cancer (7/5/2005)
A large multicenter international trial has shown that oral Hycamtin ( topotecan) has activity in the treatment of relapsed non-small cell lung cancer (NSCLC).
Oral Hycamtin® and Platinol® Regimen Active in Small Cell Lung Cancer (7/5/2005)
A regimen of oral Hycamtin (topotecan) and IV Platinol (cisplatin) has shown comparable activity to IV etoposide and Platinol for the treatment of newly diagnosed patients with extensive small cell lung cancer (SCLC).
Family History of Early Onset Lung Cancer Increases Risk of Lung Cancer Especially in Blacks (6/23/2005)
Researchers from Karmanos Cancer Institute have reported that first-degree relatives of patients with early onset lung cancer have an increased risk of smoking induced lung cancer that is greater in black individuals than in white individuals.
Benefit of Adjuvant Chemotherapy for Operable NSCLC Confirmed (6/23/2005)
Researchers from Canada have reported that adjuvant chemotherapy with Platinol® (cisplatin) and Navelbine® (vinorelbine) improves outcomes of patients with stage Ib and II non-small cell lung cancer (NSCLC).
Velcade® Moderately Active in Non-Small Cell Lung Cancer (6/16/2005)
A multi-center phase II randomized trial has determined that Velcade (bortezomib) has significant activity as a single agent or in combination with Taxotere® (docetaxel) in patients with non-small cell lung cancer (NSCLC) who have failed at least one prior regimen.[1] A SWOG trial concluded that Velcade alone had insufficient activity as a single agent in platinum treated patients and suggested other drugs be added.[2]
Tarceva® Improves Quality of Life in Refractory NSCLC (6/16/2005)
Researchers affiliated with the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) have reported that Tarceva (erlotinib) improves the quality of life (QOL) of patients with non-small cell lung cancer (NSCLC) who have failed 2-3 chemotherapy regimens.
ProMune™ Immunotherapy Promising for Non-Small Cell Lung Cancer (6/16/2005)
Researchers from Germany have reported that adding ProMune (CPG 7909) to a taxane and platinum regimen improves the response rate of patients with non-small cell lung cancer (NSCLC).
Genetic Testing Helps Predict Response of NSCLC to Iressa® (6/9/2005)
Researchers from the United States and Europe have reported that a high epidermal growth factor receptor (EGFR) gene copy number, identified by fluorescence in situ hybridization (FISH), can predict responses to Iressa (gefitinib) in patients with non-small cell lung cancer (NSCLC).
Statin Use Associated with Decreased Incidence of Prostate, Lung and Breast Cancer (5/31/2005)
Three studies were reported at the 2005 meeting of the American Society of Clinical Oncology that suggest statins are active in reducing the risk of developing prostate, lung and breast cancer.
Addition of Telcyta™ Improves Outcomes in Non-Small Cell Lung Cancer (5/23/2005)
Results from two early clinical trials indicate that the addition of Telcyta (TLK286) to chemotherapy provides high activity as initial therapy in advanced non-small cell lung cancer.
Camptosar®/Platinol® Equivalent to VePesid®/Platinol® in Extensive-Stage Small Cell Lung Cancer (5/17/2005)
Results from a “late-breaking” study indicate that the chemotherapy combination consisting of Camptosar (irinotecan) plus Platinol (cisplatin) provides similar long-term outcomes to VePesid (etoposide) plus Platinol as initial therapy in extensive small cell lung cancer (SCLC). However, due to different side effect profiles, individualized treatment including either of these regimens in the treatment of extensive SCLC may be utilized.
Targretin® Improves Survival in Advanced Non-Small Cell Lung Cancer in Patients with Hyperlipidemia (5/16/2005)
Results recently presented at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO) indicate that Targretin (bexarotene) in addition to carboplatin/paclitaxel improves survival compared to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with hyperlipidemia. Conversely, the addition of Targretin to chemotherapy does not improve survival compared to chemotherapy alone in patients with advanced NSCLC who do not have hyperlipidemia.
AvastinTM Improves Survival in Advanced Non-Small Cell Lung Cancer (5/15/2005)
Researchers affiliated with the Eastern Cooperative Oncology Group (ECOG) recently reported that the addition of Avastin (bevacizumab) to the chemotherapy regimen paclitaxel and carboplatin improves survival compared to the chemotherapy regimen alone in advanced, non-squamous, non-small cell lung cancer (NSCLC). These results were reported at a plenary session at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO).
Five-Year Experience with CT Screening for Lung Cancer (5/11/2005)
Researchers form the Mayo Clinic have reported their 5 year experience with computerized tomography (CT) screening for lung cancer and concluded that this technique allows early detection with an associated high rate of benign nodules.
Taxotere® and Gemzar®: A Well Tolerated First Line Therapy for NSCLC (5/9/2005)
Researchers from Greece have reported that a regimen of Taxotere® (docetaxel) and Gemzar® (gemcitabine) treatment of advanced non-small cell lung cancer (NSCLC) is equally effective to a regimen of vinorelbine plus cisplatin with fewer side effects.
Specific Mutations Associated with Improved Survival with Iressa® in Non-Small Cell Lung Cancer (5/8/2005)
Researchers from Korea have reported that specific mutations within the epidermal growth factor receptor (EGFR) pathway are associated with improved survival in patients with non-small cell lung cancer (NSCLC) treated with Iressa® (gefinitib).
Iressa® May Improve Symptoms and Quality of Life of Patients with NSCLC (4/29/2005)
A multi-center phase II trial of oral Iressa® (gefitinib) is reported to show improvement in symptoms and quality of life in patients with refractory non-small cell lung cancer. The details of this report appeared as an early on line publication of February 7, 2005 of the Journal of Clinical Oncology.
International Conference Recommends Lung Cancer Screening (4/27/2005)
The Como International Conference Position Statement on lung cancer screening has concluded that high-risk individuals should be encouraged to enroll in ongoing trials evaluating lung screening. In the U.S., this primarily means studies of annual computerized tomography (CT) scans.
Patients with Lung Cancer Have High Incidence of Second Primary Cancers (4/20/2005)
Researchers from the Leiden University in the Netherlands have reported that patients with non-small cell lung cancer (NSCLC) have a high incidence of previous and subsequent primary cancers. The details of this retrospective analysis were reported in the April 2005 issue of Chest.
Radiofrequency Ablation Effective for Inoperable Lung Cancer and Lung Metastasis (4/11/2005)
According to results presented at the 30th annual meeting of the Society of Interventional Radiology, radiofrequency ablation appears to be an effective treatment strategy for patients with inoperable early stage non-small cell lung cancer (NSCLC), or cancer metastatic to the lung.
The NCI Announces That Avastin™ with Chemotherapy Prolongs Survival in Non-Squamous NSCLC (3/15/2005)
A National Cancer Institute (NCI) press release on March 14, 2005 announced that a randomized trial performed by the Eastern Cooperative Group (ECOG) showed that the combination of paclitaxel, carboplatin and Avastin™ (bevacizumab) prolonged survival of patients with non-small cell lung cancer (NSCLC) when compared to chemotherapy alone.
New Synthetic Anthracycline, Amrubicin, Shows Promise for the Treatment of Small Cell Lung Cancer (3/14/2005)
Researchers from Japan have determined that a new synthetic anthracycline in combination with cisplatin (Platinol®) has significant activity in newly diagnosed extensive small cell lung cancer (SCLC). The details of this phase I/II study appeared in the March 2005 issue of the Annals of Oncology.
Surgical Resection of Brain Metastasis in Primary Motor Cortex Feasible (3/1/2005)
Researchers from the Cleveland Clinic, Vanderbilt University and the National Institutes of Health recently reported that complete surgical resection of brain metastasis within the motor cortex of the brain is an effective and feasible practice in patients with cancer. These results were reported in the February 20, 2005 edition of the Journal of Clinical Oncology.
First-Line Treatment with Taxotere® and Platinol® in NSCLC Shows Activity with Good Safety Profile (2/16/2005)
A recent French study in the January 2005 issue of Annals of Oncology reports that first-line treatment with Taxotere® (docetaxel) and Platinol® (cisplatin) was marginally superior to the combination of Navelbine® (vinorelbine) and Platinol® for the initial treatment of patients with stage IV non-small cell lung cancer (NCSLC).
More Evidence that Passive Smoking Causes Lung Cancer (2/11/2005)
Researchers affiliated with the International Agency for Research on Cancer confirm that “environmental tobacco smoke is a risk factor for lung cancer and other respiratory diseases, particularly in ex-smokers.” Researchers from Hong Kong also “found significant dose-dependent associations between passive smoking and mortality from lung cancer, chronic obstructive pulmonary disease, stroke, ischaemic heart disease, and from all cancers, all respiratory and circulatory diseases, and all causes.”
More Evidence that Chemotherapy Improves Survival in Elderly with Non-Small Cell Lung Cancer (2/11/2005)
Researchers from the Fred Hutchinson Cancer Research Center recently reported that the addition of chemotherapy in the treatment regimen of the elderly with non-small cell lung cancer (NSCLC) improved survival.
Weekly Taxotere® a Reasonable Palliative Second-Line Option for NSCLC (2/10/2005)
Researchers from France have compared a weekly schedule of Taxotere® (docetaxel) to an every-three-week schedule of Taxotere® for second-line treatment of non-small cell lung cancer (NSLC) and concluded that the weekly schedule had a better safety profile, especially for neutropenia.
The Environmental Protection Agency Issues Health Advisory on Radon to Prevent Lung Cancer (2/8/2005)
On January 15, 2005 the US Environmental Protection Agency (EPA) urged Americans to test for radon gas in their homes to prevent lung cancer. In a separate report, researchers from Europe published the latest analysis of the effect of radon in homes and the risk of lung cancer in the February issue of the British Journal of Medicine.
PET Scans More Accurate in Detecting Mediastinal Lymph Node Metastasis in NSCLC (2/2/2005)
According to a metanalysis published in the January 2005 issue of Annals of Thoracic Surgery, positron emission tomography (PET) scans are much more accurate that CT scans in detecting mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC).
Randomized Study Confirms Efficacy of Gemzar® and Carboplatin for Advanced NSCLC (2/1/2005)
According to the results of a study recently published in the January 1, 2005 issue of the | |
Patient Home
